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Abstract 
Purpose:  To evaluate the efficacy of intravitreal bevacizumab (IVB) in eyes with 
polypoidal choroidal vasculopathy (PCV). 
Methods:  Seventeen eyes of 16 patients with subfoveal or juxtafoveal PCV were 
treated with IVB.  As an initial treatment, 10 eyes were treated with a single injection 5 
of bevacizumab and 7 eyes were treated with 3 monthly injections.  Additional IVB 
injections were performed in 15 eyes when a recurrent or residual exudative change 
was seen.  Follow-up after initiation of IVB ranged from 12 to 30 months (mean, 20.7 
± 5.7 months). 
Results:  The mean foveal thickness before IVB (492 ± 205 µm) was decreased to 10 
384 ± 181 µm at three months (P = 0.0008), and with additional IVB for recurrent 
exudative changes, the foveal thickness was still reduced significantly at 12 months 
(392 ± 203 µm, P = 0.0270).  Mean visual acuity at baseline (0.54 ± 0.38 in logMAR) 
somewhat improved to 0.45 ± 0.32 at three months (P = 0.156).  However, the 
improvement in visual acuity then subsided, and returned to the pretreatment value at 15 
12 months (0.54 ± 0.39).  Conclusions:  In eyes with PCV, IVB can reduce the 
exudative change and can maintain visual function for at least one year. 
Key words:  age-related macular degeneration; bevacizumab; polypoidal choroidal 
vasculopathy 
20 
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Introduction 
It is generally thought that vascular endothelial growth factor (VEGF) plays a central 
role in the formation and development of choroidal neovascularization (CNV) in 
age-related macular degeneration (AMD).1, 2  Visual prognosis in eyes with subfoveal 
CNV secondary to AMD is poor.  Recently, a number of reports have shown 5 
promising effects of bevacizumab (Avastin; Genentech, South San Francisco, 
California), which is a recombinant humanized monoclonal antibody that binds to 
VEGF, for CNV secondary to AMD.3 
     Polypoidal choroidal vasculopathy (PCV) was first described as a new clinical 
entity with a unique form of choroidal vascular abnormality, which is characterized by 10 
a branching vascular network that terminates in polypoidal lesions seen on 
indocyanine green angiography.4-6  However, Maruko et al.7 recently reported that 
5.5% of patients with exudative AMD showed PCV lesions in one eye and typical AMD 
lesions in the other eye.  It is still controversial whether PCV is a distinct clinical entity 
or represents an unusual form of AMD.8  Similar to AMD,9 it has been reported that 15 
VEGF concentrations in aqueous humor are markedly increased in eyes with PCV.10  
The involvement of VEGF in the formation of PCV is also suggested by histologic 
specimens.11  Therefore, it may well be that anti-VEGF therapy is effective for the 
treatment of PCV. 
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     Recently, several investigators have reported the effects of intravitreal 
bevacizumab (IVB) for the treatment of exudative PCV.12-19  Even though the 
polypoidal lesions sometimes persist after IVB injection, retinal thickness is reported 
to be decreased shortly after the initiation of such treatment.13-15, 17  In eyes with PCV, 
however, the effects of IVB on visual acuity (VA) remain controversial.13-15, 17  In 5 
addition, because these previous reports have only a short follow-up period, limited 
information is available on the long-term efficacy of IVB in eyes with PCV.13  
Accordingly, the study described herein was designed to study for at least one year 
the effects of IVB administered for the treatment of PCV. 
10 
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Material and Methods 
For this interventional case series, we studied retrospectively the medical records of 
17 eyes (16 patients) with active PCV that were treated with IVB at Kyoto University 
Hospital from October 2006 to April 2008.  All eyes had a minimum follow-up period 
of 12 months after the initial treatment with IVB.  The eligibility criteria were active 5 
PCV with a visual disturbance and treatment with IVB.  The diagnosis of PCV was 
based on indocyanine green angiography, which shows a branching vascular network 
that terminates in polypoidal swelling.  In the current study, 15 eyes showed either a 
polypoidal lesion, a branching vascular network, or type 2 CNV beneath the center of 
the fovea.  Two eyes showed a serous pigment epithelial detachment (PED) just 10 
beneath the fovea with adjacent juxtafoveal polypoidal lesions.  Eyes with other 
macular abnormalities (i.e., AMD, pathologic myopia, idiopathic CNV, presumed 
ocular histoplasmosis, angioid streaks and other secondary CNV) were excluded from 
the current study.  In the present study, pseudophakic eyes were included, but eyes 
with a history of vitrectomy were excluded.  Eyes that had undergone photodynamic 15 
therapy (PDT) for PCV within four months were also excluded from the current study.  
The current study was approved by the Institutional Review Board at Kyoto University 
Graduate School of Medicine and adhered to the tenets of the Declaration of Helsinki.  
Written informed consent was obtained from each patient. 
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     In the study described herein, patients who had a subjective visual disturbance 
due to subfoveal or juxtafoveal PCV were offered IVB, the dosage of which was 1.25 
mg/0.05 ml per injection.  All injections were performed in a sterile manner and 
prophylactic topical antibiotics were applied for 1 week after IVB injection.  As initial 
treatment, 10 eyes were treated with a single injection of bevacizumab and 7 eyes 5 
were treated with 3 monthly injections.  Each patient was scheduled to visit our clinic 
for an examination at a 1-2 month interval.  After the initial treatment, when recurrent 
or residual exudative changes due to PCV were seen by optical coherence 
tomography (OCT) examination or on a fundus examination, additional IVB injections 
were given. 10 
     At each visit, all patients underwent a comprehensive ophthalmologic 
examination, including best-corrected VA testing, intraocular pressure measurement, 
indirect ophthalmoscopy, slitlamp biomicroscopy with a contact lens, fundus 
photography, and OCT.  Best-corrected VA was measured with a Landolt chart.  
Fluorescein and indocyanine green angiography were performed on each patient 15 
using a confocal laser scanning system (HRA-2; Heidelberg Engineering, Heidelberg, 
Germany) before and at 3-6 months after the treatment.  Additional angiography was 
performed as necessary. 
     In this study, spectral-domain OCT was used at the baseline examination and at 
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follow-up visits.  At each visit, all patients underwent examination by OCT of 
cross-sections centered on the fovea as well as OCT of additional sections.  
Because eyes with PCV often showed serosanguineous pigment epithelial 
detachment, foveal thickness was defined as the distance between the inner surface 
of the neurosensory retina and the thin straight line of Bruch’s membrane.14 5 
     All values are presented as mean ± standard deviation.  For statistical analysis, 
best-corrected VA measured with a Landolt chart was converted to a logarithm of the 
minimal angle of resolution (logMAR).  Paired t-test was used to evaluate changes in 
VA and foveal thickness.  In each eye, VA was considered to be improved or 
deteriorated when the change in VA (logMAR) was greater than 0.3.  Statistical 10 
software (Statview 5.0; SAS Institute, Cary, North Carolina) was used for statistical 
analyses.  A P value < 0.05 was considered to be statistically significant. 
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RESULTS 
In the current study, 17 eyes of 16 patients (14 men and 2 women), ranging in age 
from 60 to 85 years (74.8 ± 6.2 years), underwent IVB injection for the treatment of 
subfoveal or juxtafoveal PCV (Table 1).  While 3 of 17 eyes had undergone PDT 
previously, all eyes showed active exudative changes due to their PCV.  No eyes had 5 
been treated previously with either local or systemic anti-VEGF therapy.  
Examination just before initiation of the IVB treatment showed polypoidal lesions in 14 
eyes, branching vascular network in all 17 eyes, type 2 CNV in 3 eyes, serous retinal 
detachment in 9 eyes, and PED in 10 eyes.  Of the 17 eyes, subfoveal findings were 
polypoidal lesions in 4 eyes, a branching vascular network in 11 eyes, and PED in 2 10 
eyes.  Pretreatment VA on a Landolt chart ranged from 0.09 to 1.2 (median, 0.3): five 
of the 17 eyes had a VA of better than 0.5 (median, 0.8) before treatment.  Fifteen 
eyes received additional IVB injections.  Mean total injections was 4.0 ± 1.7, ranging 
from 1 to 6.  Follow-up after the initiation of IVB ranged from 12 to 30 months (mean, 
20.7 ± 5.7 months). 15 
     Figure 1 shows the change in VA and in foveal thickness after IVB injection.  
IVB treatment reduced substantially the exudative change after initiation of the 
treatment in 13 eyes (Fig. 2).  The mean foveal thickness (492 ± 205 µm before 
treatment) was decreased significantly to 384 ± 181 µm (P = 0.0008) at three months.  
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After this successful initial treatment, however, six eyes showed a recurrence of the 
exudative change (Fig. 3).  Repeated angiography confirmed a recurrence of 
polypoidal lesions in two eyes.  With additional IVB, foveal thickness at 12 months 
(392 ± 203 µm) was still reduced significantly compared with pretreatment 
measurements of thickness (P = 0.0270).  The mean VA before treatment (0.54 ± 5 
0.38 in logMAR) also somewhat improved, being 0.45 ± 0.32 (P = 0.156) at three 
months; the difference was not statistically significant.  Unfortunately, the 
improvement in VA subsided thereafter.  At 12 months, mean VA had returned to the 
pretreatment value (0.54 ± 0.39).  At 12 months, two eyes showed a significant 
improvement in VA and no eye showed a significant decrease in VA.  Whether a 10 
single injection of IVB or 3 monthly IVB injections were given as the initial treatment, 
there was no significant difference in changes of either the VA or of the foveal 
thickness. 
     In the current study, 14 eyes showed polypoidal lesions just before treatment 
with IVB, while postoperative angiography showed the polypoidal lesions to have 15 
disappeared in 9 eyes (Fig. 4).  In no eye, however, had the branching vascular 
network disappeared.  In addition, 3 eyes showed type 2 CNV just before the 
initiation of IVB.  On postoperative angiography, leakage from the type 2 CNV had 
disappeared completely in 2 eyes and was substantially decreased in the other eye. 
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     Figure 5 shows the change in VA and in foveal thickness after IVB in 5 eyes that 
had a good initial VA (better than 0.5 on a Landolt chart).  The exudative change was 
reduced after the initiation of IVB treatment in all 5 of these eyes, and after this 
successful initial treatment, recurrent exudative change or macular edema was 
treated with additional IVB injections.  The mean VA (0.10 ± 0.11 in logMAR before 5 
treatment) was maintained at 12 months (0.13 ± 0.12) in all 5 eyes; one eye, however, 
developed a tear of the retinal pigment epithelium at 3 months after 3 monthly IVB 
injections (Fig. 6).  
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Discussion 
PCV is thought to have a better visual prognosis than does AMD.20  However, when 
the abnormal choroidal vasculature with exudative change extends to the subfoveal 
area, visual prognosis usually is poor.  Direct laser photocoagulation has been 
applied to eyes with PCV.21  However, unless the entire lesion including the 5 
polypoidal lesion and a branching vascular network is successfully coagulated, the 
polypoidal lesion and exudative change often recur, resulting in decreased VA.22  A 
number of studies, however, have shown encouraging results of PDT for PCV.23-25  In 
a report by Chan et al.,23 PDT resulted in stable or improved VA in 95% of eyes with 
PCV one year after treatment.  However, recent studies have shown that visual 10 
prognosis of PCV treated with PDT is not so promising.26-28  One or more years after 
successful treatment with PDT, some eyes have a recurrence of PCV and, 
consequently, a decrease in VA. 
      Similar to AMD, some reports have suggested that VEGF is involved in the 
development of vascular lesions in eyes with PCV.10, 11  Recently, several 15 
investigators have reported the short-term effects of anti-VEGF therapy for the 
treatment of exudative PCV.12-19, 29  Originally, Ghajarnia et al.12 reported a case of 
refractory PCV that was successfully treated with a single injection of IVB.  Most 
subsequent reports have shown that IVB reduces the exudative change resulting from 
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PCV lesions shortly after the initiation of treatment, while exerting also an effect on the 
vascular lesions of PCV.13-15, 17   However, its effect on VA remains controversial.13-15, 
17  Gomi et al.14 reported no improvement in VA at three months after treatment of 
PCV with IVB.  In contrast, Lai et al.13 and Song et al.15 reported a significant 
improvement in VA at three months.  However, because these reports each 5 
consisted of a small number of patients, selection of patients may have influenced the 
reported efficacy of treatment.13-15, 17  In addition, because each of these reports had 
a relatively short follow-up,14, 15, 17 the long-term effect of IVB on eyes with PCV is 
uncertain. 
     In the current study, follow-up after the initiation of IVB treatment was at least 12 10 
months (mean, 20.7 ± 5.7 months).  Similar to the previous reports, IVB treatment 
reduced substantially at three months the exudative change,13, 15, 17 and with 
additional IVB to recurrent exudative change, the decreased foveal thickness could be 
maintained for 12 months.  With IVB, mean VA was also somewhat improved at three 
months.  This improvement in VA then subsided, and the mean VA returned to the 15 
pretreatment level at 12 months, even though the recurrent exudative change was 
often treated successfully with additional IVB.  Judging from the current study, eyes 
with PCV that are treated with IVB can be expected to maintain the pretreatment VA 
for at least one year. 
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     After the initial IVB treatment, our patients received additional IVB when a 
recurrent or persistent exudative change was seen.  In both the MARINA30 and 
ANCHOR31 studies, monthly treatments with ranibizumab successfully improved VA in 
eyes with AMD, while the PIER study32 showed that less frequent scheduled injections 
did not maintain the improvement in VA that was made with the initial monthly 5 
injections.  However, it is still controversial whether additional treatment with 
ranibizumab to recurrent or persistent exudative change does maintain the 
improvement in VA that had been achieved with the initial treatment.33  The PrONTO 
study33 showed a promising effect, although the SAILOR study did not.  Even with 
additional IVB, our patients did not show at the final visit the VA improvement that they 10 
had gained at three months.  Delayed treatment to the recurred exudative change 
may cause the damage of the photoreceptor cells, resulting in the poor visual 
outcome.  It is possible that more frequent IVB injections might result in more 
promising final VA.  In addition, while our patients were scheduled to visit our clinic 
for an examination at a 1-2 month interval, monthly examinations would be essential 15 
to improve visual prognosis. 
     In the current study, IVB did result in a regression of type 2 CNV secondary to 
PCV.  In 36% of eyes, however, the polypoidal lesions did not disappear with IVB, 
and it did not diminish at all the branching vascular network.  The reason why IVB is 
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less effective against the PCV lesion itself is uncertain.  One possible explanation is 
the location of the vascular lesion of PCV, which is situated beneath the retinal 
pigment epithelium.8  Another reason may be that VEGF is more weakly involved in 
vascular components of PCV than it is in CNV secondary to AMD.  Based on the 
visual prognosis of eyes with PCV that received other treatments (i.e., laser 5 
photocoagulation or PDT), the recurrence of the vascular lesion may be the most 
crucial for the long-term treatment effect on PCV.22, 26-28  In PCV, repeated treatment 
with IVB may be necessary to avoid recurrence.  Furthermore, combination therapy 
with PDT might be superior to IVB monotherapy in order to reduce recurrences.16, 18 
     The current study included five eyes with relatively good initial VA (better than 10 
0.5 on a Landolt chart), but as all eyes showed an exudative change with subfoveal or 
juxtafoveal PCV, visual prognosis may be poor without any treatments.  PDT may 
cause severe hemorrhagic complications in eyes with PCV,34 and, in the clinical 
setting, it may be difficult to treat with PDT those eyes that have PCV and good VA.  
In eyes with PCV, IVB might be safer than is PDT.  Previously, Gomi et al.14 used IVB 15 
in eyes with PCV that had good VA and maintained the initial VA for three months.  In 
the current study in which IVB was used, all 5 eyes with good initial VA maintained 
their VA for 12 months.  However, one of these five eyes developed a tear in the 
retinal pigment epithelium.  Eyes with PCV often show a serosanguineous PED,35 
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and when a large PED is seen beneath the fovea, it should be kept in mind that 
development of a tear in the retinal pigment epithelium is a possible complication of 
IVB.36 
     Limitations of the current study are the various treatment regimens used and the 
small sample size.  However, despite these short-comings, our findings suggest that 5 
IVB can maintain VA for at least 12 months in eyes with PCV.  In addition, 
Reche-Frutos et al.29 recently reported the promising short-term effects of 
ranibizumab for PCV, and anti-VEGF therapy remains an option for the treatment of 
PCV.  Therefore, prospective studies with long-term follow-up are needed to 
evaluate the safety and efficacy of IVB for the treatment of PCV. 10 
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Figure legend 
Figure 1.  Mean foveal thickness (A) and mean visual acuity (VA) in logMAR fashion 
(B) in eyes with polypoidal choroidal vasculopathy treated with intravitreal injections of 
bevacizumab. *P < 0.01, †P < 0.05, compared with pretreatment values.  Mo = 
month(s). 5 
 
Figure 2.  Polypoidal choroidal vasculopathy that was treated successfully with 
intravitreal injections of bevacizumab (patient 2).  (A) Funduscopic photograph 
shows massive subfoveal exudation with surrounding subretinal hemorrhage.  Visual 
acuity of the left eye was 0.15.  (B) Horizontal (upper) and vertical (lower) optical 10 
coherence tomographic images along white arrows shown in the fundus photograph 
reveal a sharp protrusion of retinal pigment epithelium with overlying subretinal 
exudate. (C) Fluorescein angiography reveals classic subfoveal choroidal 
neovascularization (CNV).  (D) Indocyanine green angiography reveals a branching 
vascular network terminating in two polypoidal lesions (arrow) and type 2 CNV (long 15 
arrow).  This eye was treated with 3 monthly injections of bevacizumab and 3 
additional injections.  (E) Twenty-four months after the initial treatment, funduscopic 
photograph shows fibrosis and surrounding atrophy of retinal pigment epithelium.  
Visual acuity remained at 0.15.  (F) Horizontal (upper) and vertical (lower) optical 
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coherence tomographic images along white arrows shown in the fundus photograph 
reveal minimal exudative change with a protrusion of retinal pigment epithelium.  (G) 
Fluorescein angiography shows minimal leakage.  (H) Indocyanine green 
angiography reveals disappearance of both the polypoidal lesions and the type 2 CNV, 
but the branching vascular network is still visible. 5 
 
Figure 3.  Recurrence of exudative change after successful treatment of the 
polypoidal lesion with intravitreal injections of bevacizumab (patient 15).  (A) 
Funduscopic photograph shows large pigment epithelial detachment with reddish 
orange nodules.  Visual acuity of the left eye was 0.6.  (B) Fluorescein angiography 10 
reveals occult choroidal neovascularization (CNV).  (C) Indocyanine green 
angiography shows a branching vascular network terminating in many polypoidal 
lesions.  (D) Horizontal (left) and vertical (right) optical coherence tomographic 
images along white arrows shown in the fundus photograph reveal a sharp protrusion 
of the retinal pigment epithelium with overlying subretinal exudates and retinal edema.  15 
This eye was treated with 3 monthly injections of bevacizumab.  (E) Four months 
after the initial treatment, funduscopic examination shows a decrease in the exudative 
change.  Visual acuity had improved to 0.8.  (F) Fluorescein angiography reveals no 
classic CNV.  (G) Indocyanine green angiography reveals disappearance of the 
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polypoidal lesions, but the branching vascular network is still visible.  (H) Horizontal 
(left) and vertical (right) optical coherence tomographic images along white arrows 
indicated in the fundus photograph show substantially reduced exudative change.  (I) 
Horizontal (left) and vertical (right) optical coherence tomographic images obtained at 
12 months show a recurrence of the subretinal fluid.  Visual acuity at this time was 5 
0.7. 
 
Figure 4.  Intravitreal injections of bevacizumab improved visual acuity in spite of no 
change in the polypoidal lesions or in the branching vascular network (patient 9).  (A) 
Fluorescein angiography shows classic choroidal neovascularization (CNV).  (B) 10 
Indocyanine green angiography reveals a branching vascular network that terminates 
in two polypoidal lesions (arrows).  (C) Horizontal (left) and vertical (right) optical 
coherence tomographic images along white arrows shown in the fluorescein 
angiogram reveal a sharp protrusion of the retinal pigment epithelium with an 
overlying subretinal exudate.  Visual acuity of this eye was 0.3, and it was treated 15 
with 4 injections of bevacizumab.  (D) Eight months after the initial treatment, 
fluorescein angiography shows minimal leakage.  (E) Indocyanine green 
angiography shows unchanged polypoidal lesions and unchanged branching vascular 
network.  (F) Horizontal (left) and vertical (right) optical coherence tomographic 
Bevacizumab for PCV. Tsujikawa A, et al. Page 25 
images show no exudative change but remaining cystoid spaces.  Visual acuity of 
the eye at this time was 0.5.  (G) Horizontal (left) and vertical (right) optical 
coherence tomographic images obtained at 19 months show no cystoid spaces.  
Visual acuity was improved to 0.7. 
 5 
Figure 5.  Mean foveal thickness (A) and mean visual acuity in logMAR fashion (B) 
in eyes with polypoidal choroidal vasculopathy treated with intravitreal injections of 
bevacizumab.  All of these eyes had good pretreatment visual acuity (VA) (better 
than 0.5).  *P < 0.05, compared with pretreatment values.  Mo = month(s). 
 10 
Figure 6.  A tear of the retinal pigment epithelium (RPE) seen in polypoidal choroidal 
vasculopathy after intravitreal injections of bevacizumab (patient 16).  (A) 
Funduscopic photograph shows a pigment epithelial detachment (PED) with a large 
reddish orange nodule.  Visual acuity of this eye was 1.2.  (B) Fluorescein 
angiography shows hyperfluorescence reflecting the PED.  (C) Indocyanine green 15 
angiography reveals a branching vascular network terminating in two polypoidal 
lesions (arrows) at the edge of the PED.  (D) Horizontal (left) and vertical (right) 
optical coherence tomographic images along white arrows in the fundus photograph 
show a sharp protrusion of the retinal pigment epithelium due to a polypoidal lesion 
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(arrow) at the edge of the PED.  The eye was treated with 3 monthly injections of 
bevacizumab.  (E) Three months after the initial treatment, funduscopic examination 
shows a large tear of the RPE (arrowheads).  Visual acuity had decreased to 0.8.  
(F) Fluorescein angiography shows a window defect due to a tear of the RPE.  (G) 
No polypoidal lesions are seen on indocyanine green angiography.  Folded RPE 5 
shows a blockage of the fluorescence (arrow).  (H) Horizontal (left) and vertical 
(right) optical coherence tomographic images along white arrows shown in the fundus 
photograph reveal increased choroidal fluorescence due to a lack of RPE 







Table 1.  Characteristics of eyes with polypoidal choroidal vasculopathy treated with IVB 










thickness (µm) Initial IVB 
Total 
number 
of IVB VA 
Foveal 





1 75/M/R None BVN 0.3 184 3 monthly injections 4 0.4 140 Dry 30 None 
2 68/F/L None PL 0.15 850 3 monthly injections 6 0.15 349 Fibrosis 24 None 
3 80/M/Ｒ None BVN 0.1 358 Single injection 5 0.1 763 Exudative 27 None 
 80/M/Ｌ None BVN 0.5 450 Single injection 5 0.2 756 Exudative 23 None 
4 74/M/R PDT BVN 0.1 415 Single injection 3 0.1 276 Slightly exudative 26 None 
5 79/M/L PDT BVN 0.09 500 Single injection 2 0.06 204 Fibrosis 26 None 
6 78/F/R None BVN 0.1 250 Single injection 2 0.2 59 Dry 23 None 
7 82/M/Ｒ None PL 0.5 666 Single injection 3 0.3 280 Dry 22 None 
8 80/M/Ｌ None PL 0.3 363 3 monthly injections 3 0.2 503 Fibrosis 20 None 
9 72/M/R None BVN 0.3 456 Single injection 6 0.7 232 Dry 19 None 
10 75/M/R None BVN 0.1 656 Single injection 4 0.06 652 Exudative 16 None 
11 85/M/R PDTｘ2 BVN 0.2 969 3 monthly injections 6 0.15 704 Exudative 13 None 
12 73/M/R None PED 0.7 345 Single injection 1 1.2 286 Dry 26 None 
13 60/M/L None PL 0.8 633 Single injection 2 0.7 463 Dry 19 None 
14 73/M/R None BVN 0.6 356 3 monthly injections 6 0.7 322 Slightly exudative 13 None 
15 68/M/L None BVN 0.8 432 3 monthly injections 6 0.7 381 Dry 13 None 
16 76/M/L None PED 1.2 484 3 monthly injections 4 0.4 330 Dry 12 RPE tear 
IVB, intravitreal injection of bevacizumab; PDT, photodynamic therapy; BVN, branching vascular network; PL, polypoidal lesion; PED, pigment epithelial detachment; RPE, retinal pigment 
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